InsidersTradesSigma
Follow the FULCRUM THERAPEUTICS INC stock price and the full management transaction log of the company, a listed issuer based in United States. Shares trade on the US market, under the supervision of SEC (Form 4). Market capitalisation: €294.5m. The latest transaction was reported on 26 June 2026 (Notice of proposed sale (Form 144)). Among the most active insiders: ALAN EZEKOWITZ. All data is openly available.
Analysts rate FULCRUM THERAPEUTICS INC Hold (neutral), based on 4 analysts. Average price target: US$3.50.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
1 of 1 declaration
FULCRUM THERAPEUTICS INC is a biopharmaceutical company focused on developing treatments for genetic diseases. It employs innovative approaches to target specific disease mechanisms.